QIMR Berghofer

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.


]Cl. This study highlights the "proof of concept" that improved gold(I)-based compounds could potentially be used to not only treat MM but as an alternative tool to understand the role of the Trx system in the pathogenesis of this blood disease.

Authors Sze, Jun Hui; Raninga, Prahlad V; Nakamura, Kyohei; Casey, Mika; Khanna, Kum Kum; Berners-Price, Susan J; Di Trapani, Giovanna; Tonissen, Kathryn F
Pages 101310
Volume 28
Date 1/08/2019
Grant ID
Funding Body Griffith University Postgraduate Research Scholarship
URL http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016/j.redox.2019.101310
Download Article